NGS 인포매틱스 및 임상 유전체학 시장 - 세계 및 지역 분석 : 제공, 기술, 용도, 최종사용자, 지역별 - 분석과 예측(2026-2036년)

This report can be delivered within 1 working day.

Introduction of the NGS informatics and Clinical Genomics Market

The global NGS informatics and clinical genomics market, initially valued at $3,251.4 million in 2025, is projected to grow substantially, reaching $16,650.3 million by 2036, with a compound annual growth rate (CAGR) of 15.80% from 2026 to 2036.

The global NGS informatics and clinical genomics market has been experiencing rapid growth, driven by the increasing adoption of next-generation sequencing across precision oncology, rare-disease diagnosis, newborn screening, population genomics, biobanking, biomarker discovery, drug development, and precision medicine. NGS informatics platforms are used across academic and research institutes, pharmaceutical and biopharmaceutical companies, diagnostic laboratories, hospitals, and clinics to manage samples, process sequencing data, identify genomic variants, interpret clinical significance, generate reports, and store complex genomic and multi-omics datasets. The market is supported by increasing sequencing volumes, expanding clinical applications, growing demand for AI-assisted interpretation, cloud computing, secure data storage, laboratory workflow automation, and integration with clinical and research systems. Overall, the market is moving toward integrated, interoperable, AI-enabled, and cloud-based platforms capable of managing genomic information throughout its lifecycle.

Market Introduction

The global NGS informatics and clinical genomics market represents the software, data-management, analytical, and computing layer of the sequencing ecosystem. It covers laboratory information management systems, NGS-based genomics informatics tools, NGS-based proteomics informatics tools, and storage, infrastructure, and computing platforms. These solutions support sample accessioning, workflow management, primary and secondary data analysis, variant annotation, clinical interpretation, reporting, genomic-data aggregation, secure storage, and periodic reanalysis.

The market has evolved significantly as sequencing has expanded from research-focused workflows into clinical laboratories, hospitals, pharmaceutical research, population-genomics initiatives, and precision-medicine programs. NGS informatics solutions enable organizations to convert raw sequencing output into structured and interpretable genomic information. These capabilities are increasingly important for cancer profiling, inherited-disease testing, rare-disease diagnosis, pharmacogenomics, companion diagnostics, clinical-trial development, biomarker identification, and population-level genomic research.

The market is increasingly shaped by technological advancements such as artificial intelligence, machine learning, cloud computing, automated variant interpretation, phenotype matching, clinical decision support, multi-omics data integration, long-read sequencing analysis, pangenome-aware workflows, and longitudinal genomic reanalysis. Integrated platforms are gaining importance as laboratories and research organizations seek to connect sequencing instruments, LIMS, analytical pipelines, curated genomic databases, electronic health records, clinical reports, and secure storage environments within standardized workflows.

Companies operating in the market are focusing on analytical accuracy, workflow automation, AI-assisted interpretation, scalable cloud computing, laboratory integration, clinical reporting, data security, interoperability, and evidence-management capabilities. As healthcare and life sciences organizations continue to invest in genomic testing, precision medicine, biobanking, drug discovery, and population-scale genomics, NGS informatics platforms are expected to become a critical component of global research and clinical infrastructure.

Industrial Impact

The global NGS informatics and clinical genomics market has witnessed rapid adoption, driven by the growing need to manage, process, interpret, and securely store increasingly large and complex genomic datasets. Key players such as SOPHiA GENETICS, DNAnexus, Inc., DNASTAR, Thermo Fisher Scientific, Inc., QIAGEN N.V., Agilent Technologies, Inc., GenomOncology, LLC, Illumina, Inc., Sapio Sciences, Velsera, Amazon.com, Inc. (Amazon Web Services, Inc.), Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, and Siemens AG play an important role in advancing genomic data analysis, laboratory informatics, clinical interpretation, cloud computing, and multi-omics integration.

These platforms are widely used across precision oncology, rare-disease diagnosis, inherited-disorder testing, pharmacogenomics, biomarker discovery, drug development, population genomics, infectious-disease genomics, and differential gene-expression analysis. By enabling automated data processing, variant identification, evidence-based interpretation, structured clinical reporting, cohort analysis, and secure data collaboration, NGS informatics platforms are improving analytical efficiency and supporting faster research and clinical decision-making.

The market's impact is most visible in academic and research institutes, pharmaceutical and biopharmaceutical companies, diagnostic laboratories, hospitals, and population-genomics programs managing high-volume sequencing datasets. Cloud-based and AI-enabled platforms are also expanding access to scalable computing and advanced genomic interpretation without requiring equivalent on-premises infrastructure. However, genomic-data privacy, cybersecurity risks, inconsistent variant interpretation, limited interoperability, regulatory complexity, and shortages of trained bioinformatics and clinical-genomics professionals continue to influence adoption.

Market Segmentation:

Segmentation 1: By Offering

• Laboratory Information Management Systems (LIMS)
• NGS-based Genomics Informatics Tools
• NGS-based Proteomics Informatics Tools
• Storage, Infrastructure, and Computing Platforms

NGS-Based Genomics Informatics Tools Segment to Dominate the NGS Informatics and Clinical Genomics Market (by Offering)

In 2025, the NGS-based genomics informatics tools segment accounted for the largest market share due to its extensive use in sequencing-data processing, read alignment, variant identification, annotation, clinical interpretation, and report generation. These tools are essential for converting complex sequencing datasets into usable information for oncology, rare-disease diagnosis, inherited-disorder screening, pharmacogenomics, biomarker discovery, and precision medicine. The segment is further supported by increasing clinical sequencing volumes, the development of advanced analytical algorithms, and integration with artificial intelligence, curated knowledge bases, cloud infrastructure, and clinical reporting workflows.

Segmentation 2: By Technology

• Blockchain-enabled Genomic Data Platforms
• Data Aggregation Software
• AI/Machine Learning and Cloud Computing-based Genomic Informatics Platforms
• Clinical Decision Support-based Genomic Platforms
• Others

AI/Machine Learning and Cloud Computing-Based Genomic Informatics Platforms Segment to Dominate the NGS Informatics and Clinical Genomics Market (by Technology)

In 2025, AI/machine learning and cloud computing-based genomic informatics platforms are expected to lead the market due to their ability to process, analyze, and interpret large and complex sequencing datasets efficiently. These platforms enable automated variant detection, genomic annotation, phenotype matching, biomarker identification, disease-risk assessment, and clinical interpretation while providing scalable computing capacity for increasing NGS data volumes. Their growing adoption across laboratories, hospitals, research institutes, and pharmaceutical and biopharmaceutical companies is also supported by remote data access, workflow automation, reduced dependence on on-premises infrastructure, and integration with multiomics and clinical information.

Segmentation 3: By Application

• Biomarker Discovery
• Drug Discovery
• Precision Medicine
• Differential Gene Expression
• Others

Precision Medicine Segment to Dominate the NGS Informatics and Clinical Genomics Market (by Application)

In 2025, the precision medicine segment is expected to lead the NGS informatics and clinical genomics market due to the growing use of genomic information to support personalized disease prevention, diagnosis, treatment selection, risk assessment, and patient monitoring. NGS informatics platforms allow clinicians and researchers to identify clinically relevant variants, biomarkers, therapeutic targets, and pharmacogenomic associations. The segment is further supported by the expanding use of genomic profiling in oncology, rare diseases, inherited disorders, reproductive health, and companion diagnostics, where accurate interpretation of complex sequencing data is critical.

Segmentation 4: By End User

• Academics and Research Institutes
• Pharmaceutical and Biopharmaceutical Companies
• Diagnostic Laboratories
• Hospitals and Clinics

Academics and Research Institutes to Dominate the NGS Informatics and Clinical Genomics Market (by End User)

In terms of end user, the academics and research institutes segment is expected to lead the NGS informatics and clinical genomics market. These organizations extensively use sequencing technologies and bioinformatics platforms for fundamental genomics, translational research, population studies, rare-disease research, biomarker discovery, differential gene-expression analysis, functional genomics, and therapeutic-target identification. The segment is further supported by government research funding, genomic consortia, shared sequencing facilities, high-performance computing infrastructure, and increasing adoption of AI- and cloud-based analytical tools.

Segmentation 5: By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest-of-Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest-of-Latin America
• Middle East and Africa
  • U.A.E.
  • Israel
  • Rest-of-Middle East and Africa

North America to Dominate the NGS informatics and clinical genomics Market (by Region)

In terms of region, North America is expected to lead the NGS informatics and clinical genomics market, supported by its advanced genomic-research infrastructure, high adoption of precision medicine, extensive use of NGS in oncology and rare-disease diagnosis, strong presence of genomic software and cloud-computing companies, and substantial investment in biobanks and population-genomics programs. The U.S. represents the largest country-level market, supported by major research institutions, diagnostic laboratories, pharmaceutical and biotechnology companies, healthcare systems, and national genomic initiatives.

The region's growth is also supported by increasing integration of genomic information with electronic health records, clinical-trial systems, laboratory workflows, and cloud-based research environments. While North America is expected to retain the largest market share, Asia-Pacific is anticipated to register the fastest growth from 2026 to 2036, supported by expanding genomic research, healthcare digitization, population-genomics initiatives, pharmaceutical research, and increasing investments in cloud and bioinformatics infrastructure across China, Japan, India, Australia, South Korea, and Singapore.

Recent Developments in the NGS informatics and clinical genomics Market

• In February 2026, SOPHiA GENETICS added two major U.S. integrated healthcare systems to its network. The institutions adopted the SOPHiA DDM Platform and SOPHiA DDM Enhanced Exome application to support genomic analysis for up to 60,000 patients annually across hereditary-cancer and rare-disease testing.
• In May 2026, QIAGEN N.V. announced a collaboration with NVIDIA Corporation to integrate graph-based artificial intelligence with QIAGEN N.V.'s curated bioinformatics knowledge bases. The collaboration aims to accelerate AI-driven drug discovery, genomic interpretation, biomarker discovery, and clinical decision support by combining AI infrastructure with QIAGEN Digital Insights.
• In August 2025, Illumina, Inc. released Connected Insights v5.2, expanding oncology-focused genomic interpretation and reporting capabilities. The update was designed to provide more accurate and clinically meaningful NGS interpretation for a broader range of oncology laboratories.
• In June 2024, Thermo Fisher Scientific, Inc., National University Hospital Singapore, and Mirxes signed a memorandum of understanding to develop and clinically validate advanced NGS genomic-testing solutions for cancer. The initiative aims to improve access to affordable and rapid genomic testing tailored to Southeast Asian populations and support treatment selection and early cancer detection in Singapore.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Increasing Adoption of Precision Oncology and NGS-Based Companion Diagnostics: The increasing use of genomic biomarkers for cancer classification, treatment selection, and clinical-trial matching remains a key driver for the NGS informatics and clinical genomics market. Precision-oncology testing generates complex information on mutations, copy-number alterations, gene fusions, structural variants, and other molecular changes that must be processed and interpreted before clinical decisions can be made. Laboratories require validated solutions for secondary analysis, variant annotation, evidence review, therapy matching, quality control, and clinical reporting. As additional biomarkers become associated with targeted therapies and companion diagnostics, demand is expected to increase for automated interpretation, regularly updated knowledge bases, LIMS integration, clinical decision support, and scalable computing infrastructure.

Market Challenges

Genomic Data Privacy, Cybersecurity, and Regulatory Complexity: Genomic data privacy, cybersecurity, and regulatory compliance remain major challenges for the NGS informatics and clinical genomics market. Genomic information is permanent, difficult to anonymize fully, and capable of revealing disease susceptibility and biological relationships beyond the tested individual. Hospitals, laboratories, biobanks, and pharmaceutical companies must apply strict controls to consent, collection, storage, access, secondary use, deletion, and cross-border data transfer. Vendors must therefore provide encryption, multifactor authentication, role-based access, audit trails, consent management, data-residency controls, and jurisdiction-specific compliance. These requirements increase development and deployment costs, extend procurement and validation timelines, and complicate multinational genomic-data collaboration.

Market Opportunities

Next-Generation Detector Technologies Unlocking Advanced Diagnostic Capabilities in NGS informatics and clinical genomics: Next-generation detector technologies present a major opportunity for the NGS informatics and clinical genomics market. Advances in flat-panel detectors, wireless detectors, improved detector sensitivity, higher detective quantum efficiency, dose-efficient imaging, lightweight detector design, and AI-enabled image optimization are improving the performance and usability of NGS informatics and clinical genomics systems. These technologies support better image quality, lower radiation exposure, faster acquisition, and smoother workflows across fixed, mobile, and point-of-care imaging settings. Detector innovation is also strengthening the value of retrofit NGS informatics and clinical genomics systems by allowing existing radiography rooms to be upgraded without complete replacement. As healthcare providers continue to seek better imaging performance, improved workflow efficiency, and lower radiation exposure, vendors offering advanced detector technologies and integrated software capabilities are expected to benefit.

How can this report add value to an organization?

Product/Innovation Strategy: The global NGS informatics and clinical genomics market has been divided into several key segments, including offering, technology, application, end user, and regional markets. By understanding demand across laboratory information management systems, genomics and proteomics informatics tools, clinical interpretation software, AI- and cloud-based platforms, data-aggregation solutions, clinical decision-support platforms, and storage and computing infrastructure, this report offers valuable insights for organizations seeking to refine their product and innovation strategies.

Growth/Marketing Strategy: Expansion of precision oncology, rare-disease diagnosis, newborn screening, population genomics, biobanking, pharmaceutical research, genomic reanalysis, long-read sequencing, and multiomics integration is anticipated to be central to the growth of the NGS informatics and clinical genomics market. Key developments among genomic-software providers, cloud-computing companies, clinical laboratories, healthcare systems, research institutions, and pharmaceutical and biotechnology companies are shaping adoption across research and clinical environments.

Competitive Strategy: The NGS informatics and clinical genomics market is competitive and technology-driven, with established genomics companies, laboratory informatics providers, cloud-platform companies, and specialized clinical-interpretation vendors competing through analytical accuracy, workflow automation, AI-enabled interpretation, scalability, interoperability, cybersecurity, curated knowledge bases, clinical reporting, and regulatory compliance. Key market players are strengthening their positions through product launches, acquisitions, platform integration, strategic collaborations, cloud partnerships, clinical-network expansion, and solutions connecting genomic, clinical, imaging, proteomic, and real-world data.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2036 have been considered for the global market size estimation; 2025 has been considered as the base year, and 2026 to 2036 as the forecast period.
• The scope of the report is based on comprehensive inputs from industry experts across various sectors, including NGS informatics solution providers, clinical genomics software providers, laboratory information management system providers, genomic data storage and computing platform providers, sequencing companies, clinical laboratories, hospitals, pharmaceutical and biotechnology companies, and academic and research institutions.
• Revenues from companies have been sourced from their annual reports for FY2024 and FY2025. For private companies, revenue estimates have been derived from primary research inputs, funding history, market collaborations, and operational performance.
• The market has been mapped based on the existing NGS informatics and clinical genomics products and platforms. Key companies with significant offerings in NGS informatics and clinical genomics systems have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts from the healthcare and life sciences industries and various stakeholders, such as NGS informatics solution providers, clinical genomics software providers, laboratory information management system providers, genomic data storage and computing platform providers, sequencing companies, clinical laboratories, hospitals, pharmaceutical and biotechnology companies, and academic and research institutions. Respondents such as CEOs, vice presidents, marketing directors, product managers, bioinformatics professionals, clinical geneticists, laboratory directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investors' presentations of the leading market players
• Company websites and a detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• SOPHiA GENETICS
• DNAnexus, Inc.
• DNASTAR
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• GenomOncology, LLC
• Illumina, Inc.
• Sapio Sciences (A Subsidiary of GHO Capital)
• Velsera
• Amazon.com, Inc. (Amazon Web Services, Inc.)
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies plc
• Siemens AG

Table of Contents

Executive Summary

Scope and Definition

1 Global NGS Informatics and Clinical Genomics Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Role of NGS Informatics in Precision Medicine
• 1.3 Technologies with the Potential to Incorporate NGS in a Clinical Setting
• 1.4 Market Trends
  • 1.4.1 Impact Analysis
  • 1.4.2 Increasing Adoption of Integrated, AI-Enabled Genomics and Multiomics Platforms
• 1.5 Regulatory Landscape
  • 1.5.1 North America
    • 1.5.1.1 U.S.
    • 1.5.1.2 Canada
  • 1.5.2 Europe
    • 1.5.2.1 European Union
    • 1.5.2.2 U.K.
  • 1.5.3 Asia-Pacific
    • 1.5.3.1 Japan
    • 1.5.3.2 China
    • 1.5.3.3 India
    • 1.5.3.4 Australia
    • 1.5.3.5 Singapore
  • 1.5.4 Latin America
    • 1.5.4.1 Brazil
    • 1.5.4.2 Mexico
  • 1.5.5 Middle East and Africa
    • 1.5.5.1 U.A.E.
    • 1.5.5.2 Israel
• 1.6 Market Dynamics
  • 1.6.1 Market Drivers
    • 1.6.1.1 Increasing Adoption of Precision Oncology and NGS-Based Companion Diagnostics
    • 1.6.1.2 Expansion of Genomic Testing for Rare Diseases and Newborn Screening
    • 1.6.1.3 Growth of Population-Scale Genomics and Biobank Programs
  • 1.6.2 Market Restraints
    • 1.6.2.1 Genomic Data Privacy, Cybersecurity, and Regulatory Complexity
    • 1.6.2.2 Uncertainty and Inconsistency in Genomic Variant Interpretation
  • 1.6.3 Market Opportunities
    • 1.6.3.1 Development of Longitudinal Genomic Reanalysis and Patient-Recontact Platforms
    • 1.6.3.2 Expansion of Long-Read and Pangenome-Aware Genomic Informatics

2 Global NGS Informatics and Clinical Genomics Market, by Offering

• 2.1 Laboratory Information Management Systems (LIMS)
• 2.2 NGS-based Genomics Informatics Tools
  • 2.2.1 Primary Data Analysis
  • 2.2.2 Secondary Data Analysis
  • 2.2.3 Clinical Reporting and Interpretation Software
• 2.3 NGS-based Proteomics Informatics Tools
  • 2.3.1 Primary and Secondary Data Analysis
  • 2.3.2 Clinical Reporting and Interpretation Software
• 2.4 Storage, Infrastructure, and Computing Platforms

3 Global NGS Informatics and Clinical Genomics Market, by Technology

• 3.1 Blockchain-enabled Genomic Data Platforms
• 3.2 Data Aggregation Software
• 3.3 AI/Machine Learning and Cloud Computing-based Genomic Informatics Platforms
• 3.4 Clinical Decision Support-based Genomic Platforms
• 3.5 Others

4 Global NGS Informatics and Clinical Genomics Market, by Application

• 4.1 Biomarker Discovery
• 4.2 Drug Discovery
• 4.3 Precision Medicine
• 4.4 Differential Gene Expression
• 4.5 Others

5 Global NGS Informatics and Clinical Genomics Market, by End User

• 5.1 Academics and Research Institutes
• 5.2 Pharmaceutical and Biopharmaceutical Companies
• 5.3 Diagnostic Laboratories
• 5.4 Hospitals and Clinics

6 Global NGS Informatics and Clinical Genomics Market, by Region

• 6.1 Regional Summary
• 6.2 North America
  • 6.2.1 Regional Overview
  • 6.2.2 Driving Factors for Market Growth
  • 6.2.3 Factors Challenging the Market
  • 6.2.4 Market Sizing and Forecast
    • 6.2.4.1 U.S.
      • 6.2.4.1.1 Country Overview
      • 6.2.4.1.2 Driving Factors for Market Growth
      • 6.2.4.1.3 Factors Challenging the Market
      • 6.2.4.1.4 Market Sizing and Forecast
    • 6.2.4.2 Canada
      • 6.2.4.2.1 Country Overview
      • 6.2.4.2.2 Driving Factors for Market Growth
      • 6.2.4.2.3 Factors Challenging the Market
      • 6.2.4.2.4 Market Sizing and Forecast
• 6.3 Europe
  • 6.3.1 Regional Overview
  • 6.3.2 Driving Factors for Market Growth
  • 6.3.3 Factors Challenging the Market
  • 6.3.4 Market Sizing and Forecast
    • 6.3.4.1 U.K.
      • 6.3.4.1.1 Country Overview
      • 6.3.4.1.2 Driving Factors for Market Growth
      • 6.3.4.1.3 Factors Challenging the Market
      • 6.3.4.1.4 Market Sizing and Forecast
    • 6.3.4.2 Germany
      • 6.3.4.2.1 Country Overview
      • 6.3.4.2.2 Driving Factors for Market Growth
      • 6.3.4.2.3 Factors Challenging the Market
      • 6.3.4.2.4 Market Sizing and Forecast
    • 6.3.4.3 France
      • 6.3.4.3.1 Country Overview
      • 6.3.4.3.2 Driving Factors for Market Growth
      • 6.3.4.3.3 Factors Challenging the Market
      • 6.3.4.3.4 Market Sizing and Forecast
    • 6.3.4.4 Italy
      • 6.3.4.4.1 Country Overview
      • 6.3.4.4.2 Driving Factors for Market Growth
      • 6.3.4.4.3 Factors Challenging the Market
      • 6.3.4.4.4 Market Sizing and Forecast
    • 6.3.4.5 Spain
      • 6.3.4.5.1 Country Overview
      • 6.3.4.5.2 Driving Factors for Market Growth
      • 6.3.4.5.3 Factors Challenging the Market
      • 6.3.4.5.4 Market Sizing and Forecast
    • 6.3.4.6 Rest-of-Europe
      • 6.3.4.6.1 Country Overview
      • 6.3.4.6.2 Driving Factors for Market Growth
      • 6.3.4.6.3 Factors Challenging the Market
      • 6.3.4.6.4 Market Sizing and Forecast
• 6.4 Asia-Pacific
  • 6.4.1 Regional Overview
  • 6.4.2 Driving Factors for Market Growth
  • 6.4.3 Factors Challenging the Market
  • 6.4.4 Market Sizing and Forecast
    • 6.4.4.1 China
      • 6.4.4.1.1 Country Overview
      • 6.4.4.1.2 Driving Factors for Market Growth
      • 6.4.4.1.3 Factors Challenging the Market
      • 6.4.4.1.4 Market Sizing and Forecast
    • 6.4.4.2 Japan
      • 6.4.4.2.1 Country Overview
      • 6.4.4.2.2 Driving Factors for Market Growth
      • 6.4.4.2.3 Factors Challenging the Market
      • 6.4.4.2.4 Market Sizing and Forecast
    • 6.4.4.3 India
      • 6.4.4.3.1 Country Overview
      • 6.4.4.3.2 Driving Factors for Market Growth
      • 6.4.4.3.3 Factors Challenging the Market
      • 6.4.4.3.4 Market Sizing and Forecast
    • 6.4.4.4 Australia
      • 6.4.4.4.1 Country Overview
      • 6.4.4.4.2 Driving Factors for Market Growth
      • 6.4.4.4.3 Factors Challenging the Market
      • 6.4.4.4.4 Market Sizing and Forecast
    • 6.4.4.5 South Korea
      • 6.4.4.5.1 Country Overview
      • 6.4.4.5.2 Driving Factors for Market Growth
      • 6.4.4.5.3 Factors Challenging the Market
      • 6.4.4.5.4 Market Sizing and Forecast
    • 6.4.4.6 Singapore
      • 6.4.4.6.1 Country Overview
      • 6.4.4.6.2 Driving Factors for Market Growth
      • 6.4.4.6.3 Factors Challenging the Market
      • 6.4.4.6.4 Market Sizing and Forecast
    • 6.4.4.7 Rest-of-Asia-Pacific
      • 6.4.4.7.1 Country Overview
      • 6.4.4.7.2 Driving Factors for Market Growth
      • 6.4.4.7.3 Factors Challenging the Market
      • 6.4.4.7.4 Market Sizing and Forecast
• 6.5 Latin America
  • 6.5.1 Regional Overview
  • 6.5.2 Driving Factors for Market Growth
  • 6.5.3 Factors Challenging the Market
  • 6.5.4 Market Sizing and Forecast
    • 6.5.4.1 Brazil
      • 6.5.4.1.1 Country Overview
      • 6.5.4.1.2 Driving Factors for Market Growth
      • 6.5.4.1.3 Factors Challenging the Market
      • 6.5.4.1.4 Market Sizing and Forecast
    • 6.5.4.2 Mexico
      • 6.5.4.2.1 Country Overview
      • 6.5.4.2.2 Driving Factors for Market Growth
      • 6.5.4.2.3 Factors Challenging the Market
      • 6.5.4.2.4 Market Sizing and Forecast
    • 6.5.4.3 Rest-of-Latin America
      • 6.5.4.3.1 Country Overview
      • 6.5.4.3.2 Driving Factors for Market Growth
      • 6.5.4.3.3 Factors Challenging the Market
      • 6.5.4.3.4 Market Sizing and Forecast
• 6.6 Middle East and Africa
  • 6.6.1 Regional Overview
  • 6.6.2 Driving Factors for Market Growth
  • 6.6.3 Factors Challenging the Market
  • 6.6.4 Market Sizing and Forecast
    • 6.6.4.1 U.A.E.
      • 6.6.4.1.1 Country Overview
      • 6.6.4.1.2 Driving Factors for Market Growth
      • 6.6.4.1.3 Factors Challenging the Market
      • 6.6.4.1.4 Market Sizing and Forecast
    • 6.6.4.2 Israel
      • 6.6.4.2.1 Country Overview
      • 6.6.4.2.2 Driving Factors for Market Growth
      • 6.6.4.2.3 Factors Challenging the Market
      • 6.6.4.2.4 Market Sizing and Forecast
    • 6.6.4.3 Rest-of-Middle East and Africa
      • 6.6.4.3.1 Country Overview
      • 6.6.4.3.2 Driving Factors for Market Growth
      • 6.6.4.3.3 Factors Challenging the Market
      • 6.6.4.3.4 Market Sizing and Forecast

7 Competitive Benchmarking and Company Profiles

• 7.1 Key Developments Analysis (by Company), January 2024-July 2026
• 7.2 Company Profiles
  • 7.2.1 SOPHiA GENETICS
    • 7.2.1.1 Overview
    • 7.2.1.2 Top Products/Product Portfolio
    • 7.2.1.3 Target Customers
    • 7.2.1.4 Analyst View
  • 7.2.2 DNAnexus, Inc.
    • 7.2.2.1 Overview
    • 7.2.2.2 Top Products/Product Portfolio
    • 7.2.2.3 Target Customers
    • 7.2.2.4 Analyst View
  • 7.2.3 DNASTAR
    • 7.2.3.1 Overview
    • 7.2.3.2 Top Products/Product Portfolio
    • 7.2.3.3 Target Customers
    • 7.2.3.4 Analyst View
  • 7.2.4 Thermo Fisher Scientific, Inc.
    • 7.2.4.1 Overview
    • 7.2.4.2 Top Products/Product Portfolio
    • 7.2.4.3 Target Customers
    • 7.2.4.4 Analyst View
  • 7.2.5 QIAGEN N.V.
    • 7.2.5.1 Overview
    • 7.2.5.2 Top Products/Product Portfolio
    • 7.2.5.3 Target Customers
    • 7.2.5.4 Analyst View
  • 7.2.6 Agilent Technologies, Inc.
    • 7.2.6.1 Overview
    • 7.2.6.2 Top Products/Product Portfolio
    • 7.2.6.3 Target Customers
    • 7.2.6.4 Analyst View
  • 7.2.7 GenomOncology, LLC
    • 7.2.7.1 Overview
    • 7.2.7.2 Top Products/Product Portfolio
    • 7.2.7.3 Target Customers
    • 7.2.7.4 Analyst View
  • 7.2.8 Illumina, Inc.
    • 7.2.8.1 Overview
    • 7.2.8.2 Top Products/Product Portfolio
    • 7.2.8.3 Target Customers
    • 7.2.8.4 Analyst View
  • 7.2.9 Sapio Sciences (A Subsidiary of GHO Capital)
    • 7.2.9.1 Overview
    • 7.2.9.2 Top Products/Product Portfolio
    • 7.2.9.3 Target Customers
    • 7.2.9.4 Analyst View
  • 7.2.10 Velsera
    • 7.2.10.1 Overview
    • 7.2.10.2 Top Products/Product Portfolio
    • 7.2.10.3 Target Customers
    • 7.2.10.4 Analyst View
  • 7.2.11 Amazon.com, Inc. (Amazon Web Services, Inc.)
    • 7.2.11.1 Overview
    • 7.2.11.2 Top Products/Product Portfolio
    • 7.2.11.3 Target Customers
    • 7.2.11.4 Analyst View
  • 7.2.12 Pacific Biosciences of California, Inc.
    • 7.2.12.1 Overview
    • 7.2.12.2 Top Products/Product Portfolio
    • 7.2.12.3 Target Customers
    • 7.2.12.4 Analyst View
  • 7.2.13 Oxford Nanopore Technologies plc
    • 7.2.13.1 Overview
    • 7.2.13.2 Top Products/Product Portfolio
    • 7.2.13.3 Target Customers
    • 7.2.13.4 Analyst View
  • 7.2.14 Siemens AG
    • 7.2.14.1 Overview
    • 7.2.14.2 Top Products/Product Portfolio
    • 7.2.14.3 Target Customers
    • 7.2.14.4 Analyst View

8 Research Methodology

• 8.1 Data Sources
  • 8.1.1 Primary Data Sources
  • 8.1.2 Secondary Data Sources
  • 8.1.3 Data Triangulation
• 8.2 Market Estimation and Forecast